CD8A and osteosarcoma: The PD-1/PD-L1 axis was exhausting DC vaccine-primed CD8+ T cells, contributing to the low success of DC vaccines in osteosarcoma patients, indicating that PD-1 inhibitors might improve the efficacy of DC vaccines (86).